- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07626151
Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy
Effect Of Standard Versus Restricted Fluid Therapy Guided By Electric Cardiometry On Tissue Perfuison In Robotic Prostaectomy: A Randomized Controlled Study
Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well. The main target in any surgery is what is the optimum fluid therapy to maintain the tissue perfusion and the precise balance between hazardous effects of hypervolemia that may cause delayed wound healing due to surgical anastomosis disruption or being hypovolemic that may cause tissue ischemia as acute kidney injury.
Fluid management guidance changed from static methods like central venous pressure into dynamic methods like pulse pressure variation (PPV) and stroke volume variation (SVV), which are now the most famous dynamic measures.
Electrical cardiometry is a non-invasive cardiac output monitor which uses electrical cardiometry, now a commonly used device, to measure SVV which can be used to guide fluid therapy during surgeries.
Now robotic assisted surgery is a common method in preforming many surgeries especially urological, since it's associated with numerous desirable outcomes including shorter post-operative stay and faster return to preoperative function.
With considerations related to severe Trendelenburg position and increased intra-abdominal pressure due to pneumo-peritoneum, robotic assisted surgeries are associated with many challenges in anesthesia especially the fluid therapy.
Fluid therapy in robotic surgeries is an area with growing research focus that need further exploration while there are established guidelines for fluid management in traditional surgeries, the optimal protocols for robotic surgeries are less well defined, needing more research.
We aim at this study to investigate the impact of liberal versus restricted fluid intake on the tissue perfusion reflected by serum lactate & creatinine clearance, while guiding therapy through electrical cardiometry, to reach optimum fluid protocol in prostatic robotic surgeries.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Mohamed M Mohamed, M.Sc.
- Telefonnummer: +20 111 8370641
- E-mail: mandamembo0@gmail.com
Undersøgelse Kontakt Backup
- Navn: Nazmy S Mikhael, M.D.
- Telefonnummer: +20122 7400808
- E-mail: drnazmyseif@kasralainy.edu.eg
Studiesteder
-
-
-
Cairo, Egypten
- Cairo University Hospitals
-
Kontakt:
- Mohamed M Mohamed, M.Sc.
- Telefonnummer: +20 111 8370641
- E-mail: mandamembo0@gmail.com
-
Kontakt:
- Nazmy S Mikhael, M.D.
- Telefonnummer: +201227400808
- E-mail: drnazmyseif@kasralainy.edu.eg
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male patient undergoing robotic assisted prostatectomy
- ASA I-III
Exclusion Criteria:
- ASA score more than III
- BMI more than 40
- Severe renal disease (GFR between 15 and 29)
- Previous renal surgery.
- Decompensated cardiac disease (NYHA class 3 or 4)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Liberal Group
Liberal Fluid Therapy Group
|
Patients will receive 6 ml/kg/hour of lactated ringer for maintenance in addition to fasting hours compensation (2 ml/kg for each fasting hour, given as 50% in the first hour of surgery, then 25% during the second & third hours).
An additional bolus of 200 ml Lactated Ringer will be given if MAP is below 65 mmHg.
In case of persistent hypotension despite proper fluid rescuistation, 10 mg of Ephedrine will be administered; if no response is achieved, norepinerhine infusion will start at initial dose 0.01mcg/kg/min if MAP is below 65 mmHg.
|
|
Aktiv komparator: Restricted Group
Restricted Fluid Therapy Group
|
Patients will receive 2 ml/kg as fluid bolus then 2 ml/kg/hour for maintenance, aiming at a target SVV less than 13 %.
Patients with SVV ≥ 13% will be considered fluid responder and will receive a fluid bolus of 200 ml Ringer Lactated Ringer over 10 minutes.The fluid bolus will be repeated until the SVV is less than 13%.
In case of persistent hypotension (MAP less than 65mmHg), 10 mg of Ephedrine will be administered; if no response is achieved, norepinerhine infusion will be started at intial dose 0.01mcg/kg/min if MAP is below 65 mmHg.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum Lactate level difference
Tidsramme: 24 hours
|
Serum Lactate level difference between pre-operative (baseline) value and post-operative (recovery) value in mmol/L
|
24 hours
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Ashgan R Aly, M.D., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
- Ledende efterforsker: Nazmy S Mikhael, M.D., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
- Studieleder: Mohamed M Mohamed, M.Sc., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Metaboliske sygdomme
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Prostatiske neoplasmer
- Ødem
- Hyperlaktæmi
Andre undersøgelses-id-numre
- ECGSVRFTRP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Liberal Fluid Therapy
-
Karaman Training and Research HospitalAfsluttetPostoperativ kvalme og opkastningKalkun
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institute of...AfsluttetHjertesvigt, kongestivForenede Stater
-
Bicetre HospitalRekruttering
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ikke rekrutterer endnuPatienter med radiologisk, klinisk og anamnestisk billede, der er kompatibelt med en ny diagnose af glioblastom
-
University of EdinburghNHS Lothian; Chief Scientist Office of the Scottish Government; Transfusion...AfsluttetAnæmi | Blodtransfusion | Intensiv plejeDet Forenede Kongerige
-
Hospital NordRekrutteringVæskerespons Forudsigelighed | Væske genoplivningFrankrig
-
Nanogen, Inc.Centers for Disease Control and PreventionSuspenderet
-
University Children's Hospital BaselSwiss Neonatal Network; SwissPedNetRekrutteringBronkopulmonal dysplasiSchweiz
-
Burst BiologicsUkendtFod- og ankellidelser | Ankelfusion, osteotomiForenede Stater
-
Ain Shams UniversityAfsluttetProstatasygdomme | Voiding lidelser | Prostata hyperplasiEgypten